Abstract
There are limited real-world data on fremanezumab, a fully-humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), in patients with prior exposure to other CGRP pathway-targeted mAbs such as erenumab. A US retrospective claims database study evaluated migraine-related healthcare resource utilization (HCRU) and costs for patients initiating fremanezumab treatment with common comorbidities, acute medication overuse (AMO), or difficult-to-treat migraine (DTTM) and prior erenumab exposure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
